Related Experiment Video
Updated: Mar 14, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia
Seth J Baum1, Daniel Soffer2, P Barton Duell3
1Preventive Cardiology, Inc., Boca Raton, FL.
Insights
Familial hypercholesterolemia (FH) causes extremely high LDL cholesterol, leading to early vascular disease. Management of homozygous FH is challenging as traditional treatments are often insufficient.
Area of Science:
- Cardiovascular Genetics
- Metabolic Disorders
- Pharmacogenomics
Background:
- Familial hypercholesterolemia (FH) is an autosomal co-dominant genetic disorder.
- Characterized by extremely high low-density lipoprotein (LDL) cholesterol levels.
- Associated with premature vascular disease due to genetic mutations impacting LDL clearance.
Observation:
- Mutations commonly affect genes critical for LDL receptor function.
- The LDL receptor's role in clearing circulating LDL particles is impaired.
- Most patients show insufficient response to conventional LDL-lowering medications.
Findings:
- Focuses on the clinical management strategies for homozygous FH.
- Highlights the limitations of traditional therapies in FH.
- Addresses the need for advanced therapeutic approaches.
Implications:
- Informs clinical practice for managing severe forms of FH.
- Suggests a need for novel therapeutic targets beyond LDL receptor upregulation.
- Emphasizes the importance of genetic understanding in cardiovascular disease treatment.
Abstract:
Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder marked by extremely high low-density lipoprotein (LDL) cholesterol levels and concomitant premature vascular disease. FH is caused by mutations that most commonly affect three genes integrally involved in the LDL receptor's ability to clear LDL particles from the circulation. Primary intervention efforts to lower LDL cholesterol have centered on therapies that upregulate the LDL receptor. Unfortunately, most patients are insufficiently responsive to traditional LDL-lowering medications. This article focuses primarily on the clinical management of homozygous FH.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

